ZBIO Zenas Biopharma Inc. Forecast, Technical & Fundamental Analysis

Momentum Indicator for ZBIO turns positive, indicating new upward trend

ZBIO saw its Momentum Indicator move above the 0 level on June 09, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 14 similar instances where the indicator turned positive. In of the 14 cases, the stock moved higher in the following days. The odds of a move higher are at .

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for ZBIO just turned positive on June 09, 2025. Looking at past instances where ZBIO's MACD turned positive, the stock continued to rise in of 4 cases over the following month. The odds of a continued upward trend are .

ZBIO moved above its 50-day moving average on May 15, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ZBIO advanced for three days, in of 33 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 11 cases where ZBIO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 7 cases where ZBIO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ZBIO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.520) is normal, around the industry mean (16.954). P/E Ratio (0.000) is within average values for comparable stocks, (59.376). ZBIO's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.335). Dividend Yield (0.000) settles around the average of (0.040) among similar stocks. P/S Ratio (28.818) is also within normal values, averaging (257.043).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ZBIO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ZBIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.